Alchemia Ltd (ACL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10005
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alchemia Ltd (Alchemia) is an early stage biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of various diseases. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anticoagulant drug Arixtra, approved in the US and Europe for the treatment of deep vein thrombosis and pulmonary embolism), to Dr. Reddy’s Laboratories. The company holds patents associated with VAST, its proprietary drug discovery platform. Alchemia is headquartered in South Melbourne, Victoria, Australia.

Alchemia Ltd (ACL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alchemia Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alchemia Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 12
Licensing Agreements 13
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 13
Equity Offering 14
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 14
Alchemia Completes Private Placement Of Shares For US$10.4 Million 15
Asset Transactions 16
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 16
Acquisition 17
Panther Biotech to Acquire Alchemia Oncology 17
Alchemia Ltd – Key Competitors 18
Alchemia Ltd – Key Employees 19
Alchemia Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Corporate Communications 21
Jun 06, 2018: Alchemian announces Board Change 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Alchemia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alchemia Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Alchemia Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 12
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 13
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 14
Alchemia Completes Private Placement Of Shares For US$10.4 Million 15
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 16
Panther Biotech to Acquire Alchemia Oncology 17
Alchemia Ltd, Key Competitors 18
Alchemia Ltd, Key Employees 19
Alchemia Ltd, Subsidiaries 20

List of Figures
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alchemia Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Alchemia Ltd (ACL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fortress Biotech Inc (FBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Fortress Biotech Inc (Fortress), formerly Coronado Biosciences Inc is a biopharmaceutical company that develops and commercializes pharmaceutical and biotechnology products. The company offers products in the areas of dermatology, cancer, pain management and autoimmune diseases, among others …
  • EVN AG (EVN)-エネルギー分野:企業M&A・提携分析
    Summary EVN AG (EVN) is an energy and environmental services company. It provides electricity, natural gas, heat, drinking water, wastewater treatment, thermal waste utilization, and related services. The company produces power from thermal and renewable sources. EVN procures electricity, natural ga …
  • Elbit Imaging Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Elbit Imaging Ltd (Elbit), formerly Elbit Medical Imaging Ltd is a diversified company that operates through various business segments including commercial centers, hotel, medical industries and devices, and plots in India. The company’s commercial centers segment includes initiation, constr …
  • ITT Inc.:企業の戦略・SWOT・財務分析
    ITT Inc. - Strategy, SWOT and Corporate Finance Report Summary ITT Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Exiqon AS-医療機器分野:企業M&A・提携分析
    Summary Exiqon A/S (Exiqon), a subsidiary of Qiagen NV is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company’s product categories include microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reagent pro …
  • Ted Baker PLC (TED):企業の財務・戦略的SWOT分析
    Ted Baker PLC (TED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Unigroup Inc
    Unigroup Inc - Strategy, SWOT and Corporate Finance Report Summary Unigroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • KB Home:企業の戦略・SWOT・財務情報
    KB Home - Strategy, SWOT and Corporate Finance Report Summary KB Home - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Jollibee Foods Corporation:企業の戦略・SWOT・財務情報
    Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Oaktree Capital Group Llc
    Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report Summary Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Seiko Optical Products Co Ltd:企業の戦略的SWOT分析
    Seiko Optical Products Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)-製薬・医療分野:企業M&A・提携分析
    Summary Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene reg …
  • Comtek Advanced Structures Ltd.:企業の戦略・SWOT・財務情報
    Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report Summary Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sanofi-Aventis Korea Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sanofi-Aventis Korea Co Ltd (Sanofi-Aventis), a subsidiary of Sanofi is a developer, manufacturer and distributor of generic drugs and medical equipment. The company’s products include note vials lantus, lantus state solo star, she feeds the main vial la, feed her a solo star la shares, elro …
  • Barilla Holding S.p.A.:企業の戦略・SWOT・財務情報
    Barilla Holding S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Barilla Holding S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Dr. Langer Medical GmbH:企業の戦略的SWOT分析
    Dr. Langer Medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Prinzhorn Holding Gmbh
    Prinzhorn Holding Gmbh - Strategy, SWOT and Corporate Finance Report Summary Prinzhorn Holding Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Indianola Municipal Utilities:企業の戦略的SWOT分析
    Indianola Municipal Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • ACWA Power Barka SAOG (APBS):企業の財務・戦略的SWOT分析
    ACWA Power Barka SAOG (APBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Fera Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Fera Pharmaceuticals LLC (Fera) is a pharmaceutical company that develops, markets and commercializes ointments and medicines. The company offers neptazane, bacitracin ophthalmic ointment USP, neo-polycin HC, and others. It offers various treatment options for patient and healthcare communit …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆